After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

I understand the heartbreak of watching someone you love spiral. But compassion cannot mean locking people up,” writes a STAT ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died ...

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...

Some experts worry that patient groups’ growing influence is leading to the approval of drugs that may not work and could ...

It’s been a whirlwind year so far for Sarepta and for Elevidys, which is the only FDA-approved gene therapy for Duchenne. The first fatality associated with this gene therapy was reported in March.

Sarepta Therapeutics is trading around $19 in extended hours following the FDA’s decision to remove the pause on Elevidys, marking a critical turning point for the beleaguered biotech.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS, the only approved gene therapy for patients with Duchenne ...